Cite
HARVARD Citation
Baeten, D. et al. (2018). Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Annals of the rheumatic diseases. 77 (9), pp. 1295-1302. [Online].